<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">THIOTEPA</span><br/>(thye-oh-tep'a)<br/><span class="topboxtradename">Thioplex, </span><span class="topboxtradename">TSPA<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">alkylating agent</span><br/><b>Prototype: </b>Cyclophosphamide<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>15 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Cell cycle nonspecific alkylating agent that selectively reacts with DNA phosphate groups to produce chromosome cross-linkage
         and consequent blocking of nucleoprotein synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Nonvesicant, highly toxic hematopoietic agent. Myelosuppression is cumulative and unpredictable and may be delayed. Has some
         immunosuppressive activity.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>To produce remissions in malignant lymphomas, including Hodgkin's disease, and adenocarcinoma of breast and ovary. Also in
         chronic granulocytic and lymphocytic leukemia, superficial papillary carcinoma of urinary bladder, bronchogenic carcinoma,
         and in malignant effusions secondary to neoplastic disease of serosal cavities.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prevention of pterygium recurrences following postoperative beta-irradiation; leukemia, malignant meningeal neoplasms.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to drug; acute leukemia; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Chronic lymphocytic leukemia; myelosuppression produced by radiation; with other antineoplastics; bone marrow invasion by
         tumor cells; impaired kidney or liver function.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Malignant Lymphomas</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.30.4 mg/kg q14wk <span class="rdroute">Intratumor</span> 0.60.8 mg/kg directly into tumor q14wk <span class="rdroute">Intracavitary</span> 0.60.8 mg/kg instilled through same tubing used for paracentesis at intervals of at least 1 wk <span class="rdroute">Intravesicular</span> 60 mg in 3060 mL of distilled water instilled into bladder to be retained for 2 h once/wk for 4 wk <span class="rdroute">Intrathecal</span> 110 mg/m<sub> <sup>2</sup> </sub> 12 times/wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Use only under constant supervision by physicians experienced in therapy with cytotoxic agents.</li>
<li>Avoid exposure of skin and respiratory tract to particles of thiotepa during solution preparation.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Reconstitute each 15 mg vial with 1.5 mL sterile water for injection (supplied) to yield 10 mg/mL. Further dilute with 50100
                  mL NS. Filter solution through a 0.22 micron filter to eliminate haze. Use immediately.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give 60 mg or fraction thereof over 1 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Cisplatin</b> <span class="incompattype">Y-site:</span> <b>Cisplatin,</b> <b>filgrastim,</b> <b>minocycline,</b> <b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store powder for injection and reconstituted solutions at 2°8° C (35°46° F); protect from
            light. Solutions reconstituted with sterile water only are stable for 8 h under refrigeration.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Anorexia, nausea, vomiting, stomatitis, ulceration of intestinal mucosa. <span class="typehead">Hematologic:</span> <span class="speceff-life">Leukopenia, thrombocytopenia, anemia, pancytopenia</span>. <span class="typehead">Skin:</span> Hives, rash, pruritus. <span class="typehead">Urogenital:</span> Amenorrhea, interference with spermatogenesis. <span class="typehead">Body as a Whole:</span> Headache, febrile reactions, pain and weeping of injection site, hyperuricemia, slowed or lessened response in heavily irradiated
      area, sensation of throat tightness. <span class="typehead">Other:</span> Reported with intravesical administration (lower abdominal pain, hematuria, hemorrhagic chemical cystitis, vesical irritability). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May prolong muscle paralysis with <b>mivacurium;</b> <span class="classification">anticoagulants</span>, <span class="classification">nsaid</span>s, <span class="classification">salicylates</span>, <span class="classification">antiplatelet agents</span> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly cleared from plasma. <span class="typehead">Onset:</span> Gradual response over several wk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 60% of IV dose excreted in urine within 2472 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor closely because most patients will manifest some evidence of toxicity.</li>
<li>Be aware that because of cumulative effects, maximum myelosuppression may be delayed 34 wk after termination of therapy.</li>
<li>Discontinue therapy (per manufacturer) if leukocyte count falls to 3000/mm<sup>3</sup> or below or if platelet count falls below 150,000/mm<sup>3</sup>.
         </li>
<li>Lab tests: Determine Hgb level, WBC with differential, and thrombocyte (i.e., platelet) counts at least weekly during therapy
            and for at least 3 wk after therapy is discontinued.
         </li>
<li>Monitor leukocyte and thrombocyte counts as indicators for adaptations in nursing and drug regimens.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of possibility of amenorrhea (usually reversible in 68 mo).</li>
<li>Report onset of fever, bleeding, a cold or illness, no matter how mild to physician; medical supervision may be necessary.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>